Prana Announces That PBT2 Reduces Cognitive Impairment Caused by Tau Protein Accumulation

Prana Announces That PBT2 Reduces Cognitive Impairment Caused by Tau Protein 
Accumulation 
New Data to Be Presented at the 11th International Conference on
Alzheimer's and Parkinson's Disease 
MELBOURNE, AUSTRALIA -- (Marketwire) -- 03/04/13 --  Prana
Biotechnology (NASDAQ: PRAN) (ASX: PBT) today announced the upcoming
presentation of new data demonstrating the ability of PBT2 to reduce
the damage to brain cells, caused by the accumulation of the tau
protein and preventing subsequent cognitive impairment. The tau
protein, along with the Abeta protein, are the two major proteins
associated with Alzheimer's Disease.  
The findings are consistent with the improvement in cognition
previously reported in transgenic Alzheimer's mice studies* and in
patients in a Phase IIa clinical trial with PBT2** and further
validate the metal targeting mechanism of action of PBT2. New data
will be presented by Prana scientist Associate Professor Paul Adlard
at the 11th International Conference on Alzheimer's and Parkinson's
Disease, to be held in Florence, Italy, March 6th to 10th, 2013. 
To date, Abeta has been the primary therapeutic target for disease
modifying drugs developed for Alzheimer's disease. However, the
clinical failure of several anti-Abeta drugs supports the view that
targeting Abeta alone may be insufficient to improve outcomes for
patients. The other hallmark pathological feature of Alzheimer's
disease is the presence of neurofibrillary tangles, composed of
abnormal tau protein. In his presentation, entitled "Metal Chaperones
are novel therapeutic agents for tauopathy', Associate Professor
Adlard will present new data showing that treatment with PBT2
significantly improves cognition and reduces the abundance of tau
aggregates through metal mediated mechanisms in a transgenic mouse
model of tau overexpression. 
Commenting on the significance of the new data, Rudy Tanzi, the Rose
and Joseph Kennedy Professor of Neuroscience at Harvard Medical
School and Prana's Chief Scientific Advisor, said, "These findings
provide further evidence for PBT2 as a highly attractive therapeutic
for Alzheimer's disease that targets both beta amyloid deposition and
tangle formation. Translating these dual effects into the clinic
could potentially provide tremendous benefit for patients."  
PBT2 is currently in a Phase II clinical trial, the IMAGINE trial,
which is now fully enrolled and will be completed at the end of the
year. 
* Adlard et al. Neuron (2008) vol. 59, pp. 43-55.
 ** Lannfelt et al.
Lancet Neurology (2008) vol. 7, pp. 779-86. Lannfelt et al. Errata:
Lancet Neurology (2009) vol. 8, pp. 981. 
About Prana Biotechnology Limited
 Prana Biotechnology was
established to commercialize research into age-related
neurodegenerative disorders. The Company was incorporated in 1997 and
listed on the Australian Securities Exchange in March 2000 and listed
on NASDAQ in September 2002. Researchers at prominent international
institutions including The University of Melbourne, The Mental Health
Research Institute (Melbourne) and Massachusetts General Hospital, a
teaching hospital of Harvard Medical School, contributed to the
discovery of Prana's technology.  
For further information please visit the Company's web site at
www.pranabio.com. 
Forward Looking Statements 
This press release contains "forward-looking statements" within the
meaning of section 27A of the Securities Act of 1933 and section 21E
of the Securities Exchange Act of 1934. The Company has tried to
identify such forward-looking statements by use of such words as
"expects," "intends," "hopes," "anticipates," "believes," "could,"
"may," "evidences" and "estimates," and other similar expressions,
but these words are not the exclusive means of identifying such
statements. Such statements include, but are not limited to any
statements relating to the Company's drug development program,
including, but not limited to the initiation, progress and outcomes
of clinical trials of the Company's drug development program,
including, but not limited to, PBT2, and any other statements that
are not historical facts. Such statements involve risks and
uncertainties, including, but not limited to, those risks and
uncertainties relating to the difficulties or delays in financing,
development, testing, regulatory approval, production and marketing
of the Company's drug components, including, but not limited to,
PBT2, the ability of the Company to procure additional future sources
of financing, unexpected adverse side effects or inadequate
therapeutic efficacy of the Company's drug compounds, including, but
not limited to, PBT2, that could slow or prevent products coming to
market, the uncertainty of patent protection for the Company's
intellectual property or trade secrets, including, but not limited
to, the intellectual property relating to PBT2, and other risks
detailed from time to time in the filings the Company makes with
Securities and Exchange Commission including its annual reports on
Form 20-F and its reports on Form 6-K. Such statements are based on
management's current expectations, but actual results may differ
materially due to various factions including those risks and
uncertainties mentioned or referred to in this press release.
Accordingly, you should not rely on those forward-looking statements
as a prediction of actual future results. 
Contacts:
Australia
Prana Biotechnology
+61 3 9349 4906 
US
Leslie Wolf-Creutzfeldt
T: 646-284-9472
E: leslie.wolf-creutzfeldt@grayling.com